Hypercholesterolemia: Genetics, Artery Damage, and Therapies

Hypercholesterolemia means there is too much cholesterol circulating in your blood, and it is the single most modifiable driver of atherosclerotic cardiovascular disease worldwide. The term usually refers to elevated low-density lipoprotein cholesterol (LDL-C), though the full picture involves several other lipid particles that clinicians increasingly pay attention to. What makes hypercholesterolemia tricky is that it produces no symptoms until arteries are already damaged, so most people who have it discover the fact only through a blood test or, worse, through a heart attack. Understanding what pushes cholesterol up, who is most at risk, and how the treatment landscape has evolved gives you a much better shot at staying ahead of it.

How Cholesterol Builds Up in the First Place

Your body manufactures the majority of its cholesterol internally, mostly in the liver. The rate-limiting step in that production line is an enzyme called HMG-CoA reductase, which converts a precursor molecule into mevalonate, the building block for cholesterol. When this enzyme is highly active, more cholesterol is produced; when it is dialed down, production slows.¹ Animal experiments have shown that the enzyme’s activity can spike sevenfold within a couple of hours when the body senses a need for more cholesterol, confirming how tightly it controls the pace of production.²

Production is only half the equation. Clearing cholesterol from the bloodstream depends heavily on LDL receptors on the surface of liver cells. These receptors grab LDL particles and pull them inside the cell for recycling. When the receptors are abundant and working well, LDL-C stays low. When they are scarce or defective, LDL particles pile up in the blood.³ Anything that tips the balance toward overproduction or under-clearance can push you into hypercholesterolemia.

Genetic Causes and Who Gets Hit Hardest

Familial hypercholesterolemia (FH) is the best-known genetic form. It is caused by mutations in a handful of genes, most commonly LDLR (the gene for the LDL receptor itself), APOB (the gene for the protein LDL particles use to dock with that receptor), and PCSK9 (a gene whose protein marks LDL receptors for destruction). Cataloging efforts in Russia alone have documented over 220 distinct variants across these three genes, with more than a third unique to that population.⁴ The global picture is even more diverse, which is one reason genetic testing for FH varies in sensitivity depending on your ethnic background.

Not everyone with severely high cholesterol carries one of these single-gene mutations, though. In a study of over 300 people with LDL-C above roughly 190 mg/dL, about half had a classic monogenic FH mutation. When researchers also looked for rare copy-number changes and scored the cumulative effect of many common gene variants, the proportion with a detectable genetic explanation rose to about two-thirds. Among those with the most extreme levels (above roughly 310 mg/dL), a genetic explanation could be found in over 90% of cases.⁵

The polygenic form matters a lot in everyday practice. Among people who meet clinical criteria for FH but carry no identifiable single-gene mutation, the polygenic explanation, meaning a pile-up of many common cholesterol-raising gene variants, is the most likely cause in over 80% of cases.⁶ This distinction is clinically meaningful because family members of someone with polygenic high cholesterol are less likely to have the same extreme levels than family members of someone with a monogenic mutation.

Secondary Causes Worth Ruling Out

Before assuming genetics is the whole story, clinicians look for treatable conditions that push cholesterol up on their own. Hypothyroidism is the most common secondary cause of high cholesterol after dietary factors. A sluggish thyroid reduces LDL receptor activity in the liver, so LDL particles accumulate in the bloodstream. Checking thyroid hormone levels is standard practice whenever a new case of significant hypercholesterolemia turns up. Other secondary contributors include poorly controlled diabetes, nephrotic syndrome, certain liver diseases, and medications such as some diuretics and immunosuppressants. Correcting the underlying condition often brings cholesterol down without dedicated lipid-lowering drugs.

Why LDL-C Is Not the Whole Story

Standard blood panels report LDL-C, but a growing body of evidence suggests that apolipoprotein B (apoB), the protein carried by each atherogenic lipoprotein particle, is a more accurate gauge of cardiovascular risk. When apoB levels and LDL-C levels disagree in a given person, the risk tracks with apoB, not LDL-C. A recent analysis in the Journal of Clinical Lipidology concluded that neither LDL-C nor non-HDL-C is an adequate stand-in for apoB and argued that apoB should be the primary clinical measure.⁷ Data from the Framingham Heart Study reinforced the point: when people had higher apoB than their LDL-C would predict, their coronary risk was meaningfully elevated.⁸

Particle size adds another layer. Smaller, denser LDL particles are more prone to slipping into artery walls and more susceptible to oxidation, both of which accelerate plaque formation. Clinical reviews have identified small dense LDL as an independent risk factor with stronger predictive power than total LDL-C for coronary disease and metabolic syndrome.⁹ A newer equation for estimating small dense LDL from a standard lipid panel outperformed other lipid markers, including measured small dense LDL, in predicting cardiovascular events in a large multiethnic cohort.¹⁰

Then there is lipoprotein(a), or Lp(a), a genetically determined variant of LDL that carries an extra protein called apolipoprotein(a). The American Heart Association classifies high Lp(a) as an independent, causal risk factor for atherosclerotic disease, driven by increased plaque formation, inflammation, and clotting. Around 70 to 90% of the variation in Lp(a) levels between people is genetic, so diet and exercise do little to change it.¹¹ In people who already have familial hypercholesterolemia, elevated Lp(a) roughly doubles the cardiovascular risk beyond what their LDL-C alone would predict.¹² It can also increase cardiovascular risk even when LDL-C is within the recommended range, which is sometimes called residual cardiovascular risk.¹³

How Excess Cholesterol Damages Arteries

High circulating LDL is dangerous because the particles can lodge in artery walls, where they undergo chemical oxidation. Oxidized LDL triggers a cascade of inflammation: immune cells called macrophages engulf the oxidized particles, becoming bloated “foam cells” that are a hallmark of early atherosclerosis.¹⁴ The accumulation of oxidized LDL in the inner lining of arteries is what kicks off plaque development.¹⁵ Over years and decades, these plaques grow, stiffen, and can eventually rupture, triggering the blood clots responsible for heart attacks and strokes.

The damage is not limited to coronary arteries. Oxidized LDL also promotes calcification of heart valves. Animal models fed high-cholesterol diets develop bone-like mineral deposits in their aortic valves through a signaling pathway that mirrors actual bone formation.¹⁶ Oxidized LDL drives this process in part by triggering a stress response inside valve cells that pushes them toward becoming bone-like.¹⁷ Calcific aortic stenosis, the progressive stiffening and narrowing of the aortic valve, is increasingly recognized as partly a cholesterol-driven disease, which helps explain why people with FH develop valve problems at younger ages than the general population.

The Treatment Toolbox

Statins remain the backbone of treatment. They work by blocking HMG-CoA reductase, the enzyme that controls cholesterol production. With less cholesterol being made inside liver cells, the cells respond by putting more LDL receptors on their surface, pulling LDL out of the bloodstream more efficiently.¹⁸ This dual action, less production plus greater clearance, is why statins are so effective and why they have been the first-line treatment for decades.

When statins alone are not enough, ezetimibe is typically added. It works in the gut, blocking a transporter protein called NPC1L1 that ferries cholesterol across the intestinal wall into your body.¹⁹ Structural studies have shown that ezetimibe physically plugs the tunnel through which cholesterol would otherwise travel into intestinal cells.²⁰ The combination of a statin plus ezetimibe attacks cholesterol from two directions at once: reducing what the liver makes and reducing what the gut absorbs.

PCSK9 inhibitors represent a newer class. PCSK9 is a protein that tags LDL receptors for destruction; blocking it allows the receptors to survive longer and clear more LDL from the blood. Two injectable monoclonal antibodies (evolocumab and alirocumab) and a newer small interfering RNA called inclisiran are currently available. All produce large reductions in LDL-C, though their long-term safety profiles are still being established.²¹ For people who cannot tolerate statins, bempedoic acid offers an alternative by blocking an earlier step in the same cholesterol production pathway, while evinacumab, a monoclonal antibody against a protein called ANGPTL3, provides a further option for people with refractory hypercholesterolemia.²²

Diet, Saturated Fat, and the Gut Microbiome

Reducing saturated fat intake is the oldest dietary strategy for lowering LDL-C, and the mechanism is well documented. In healthy volunteers, switching to a low-saturated-fat diet increased the number of LDL receptors on white blood cells by about 10%, which corresponded to roughly a 12% drop in LDL-C.²³ Animal experiments have confirmed that saturated fats, particularly those from coconut oil, suppress LDL receptor production in the liver at the genetic level compared to unsaturated fats from sources like safflower oil.²⁴

The picture has some nuance, though. Primate data suggest that when polyunsaturated fat intake is adequate and there is no excess dietary cholesterol, saturated fat raises LDL-C primarily by shifting cholesterol from tissues into the bloodstream rather than by suppressing LDL receptors. The receptor-suppressing effect of saturated fat becomes more pronounced when other factors have already pushed the system into a hyperlipidemic state.²⁵ In practical terms, cutting saturated fat helps most in people whose cholesterol is already elevated or whose overall dietary pattern is already tilted toward excess calories and cholesterol.

More recent research has turned to the gut microbiome. Certain bacteria, including species of Lactobacillus and Bifidobacterium, produce enzymes called bile salt hydrolases that alter the composition of bile acids in the gut. This changes signaling to the liver through a receptor pathway that ultimately ramps up the conversion of cholesterol into bile acids, effectively lowering blood cholesterol. In a mouse model of hypercholesterolemia, oral administration of a bacterial strain engineered to express high levels of bile salt hydrolase significantly reduced serum cholesterol and boosted populations of Bifidobacterium pseudolongum in the gut.²⁶ Whether probiotic or prebiotic strategies will translate into meaningful cholesterol reductions in humans remains an open question, but the biology is plausible enough that clinical trials are underway.

The Cholesterol Paradox in Older Adults

Here is where the evidence gets genuinely confusing. Among older adults, the relationship between cholesterol and mortality appears to reverse. A systematic review of cohort studies in people over 60 found that in the majority of cohorts, representing over 90% of the individuals studied, higher LDL-C was associated with lower overall mortality. Several of those associations reached statistical significance. For cardiovascular-specific death, the pattern was less clear, but none of the cohorts showed the straightforward “higher LDL, higher risk” relationship seen in younger populations.²⁷

A study of community-dwelling older adults in China found similar results: higher total cholesterol and LDL-C were linked to a lower risk of cardiovascular death after adjusting for other factors. However, the protective association disappeared once LDL-C rose above roughly 160 mg/dL, and remnant cholesterol (cholesterol carried by triglyceride-rich particles) remained harmful regardless of age.²⁸ A separate pooled analysis of patients referred for cardiac imaging similarly found that a diagnosis of hypercholesterolemia was associated with lower, not higher, mortality, though the authors cautioned that this likely reflects confounding from factors like statin use and more aggressive medical care in people labeled with the diagnosis.²⁹

This does not mean high cholesterol is harmless in old age. The paradox may partly reflect survival bias: people most susceptible to cholesterol-driven disease have already died by their 70s and 80s, leaving a population of survivors in whom cholesterol plays a smaller role. Very low cholesterol in elderly people can also signal malnutrition, cancer, or chronic inflammation, all of which raise mortality for reasons that have nothing to do with lipids. The clinical takeaway is that aggressive cholesterol lowering in otherwise healthy elderly patients deserves a more individualized risk-benefit conversation than it does in middle-aged adults.

Screening and Treatment in Children

Because atherosclerosis begins in childhood, early detection of familial hypercholesterolemia has real stakes. Japanese guidelines recommend that once a child is diagnosed with FH, lifestyle guidance including diet should begin immediately. If LDL-C remains above 180 mg/dL despite those measures, drug therapy with a statin should be considered at age 10, with a target of getting LDL-C below 140 mg/dL.³⁰

European guidelines are more aggressive on timing. A 2025 European Atherosclerosis Society consensus statement proposes starting medication for heterozygous FH in the first decade of life, ideally from age 6, with the exact timing decided by the treating physician and the family. LDL-C targets are set at roughly 135 mg/dL for children aged 6 to 9, dropping to about 115 mg/dL from age 10 onward or earlier if additional risk factors are present.³¹ The rationale is straightforward: the longer arteries are exposed to high LDL-C, the greater the cumulative damage. Starting treatment years earlier buys decades of protection.

Gene Editing on the Horizon

The newest frontier in treating hypercholesterolemia is in vivo gene editing, meaning changing your DNA with a single infusion rather than taking a pill every day or getting injections every few weeks. Two early-phase clinical programs have reported striking results. VERVE-102 uses a base-editing approach delivered by lipid nanoparticles to permanently disable PCSK9 production in the liver. At the highest dose tested, participants saw an average 88% reduction in PCSK9 protein and a 62% drop in LDL-C, an absolute reduction of about 78 mg/dL. Those reductions appeared to hold steady for at least a year.³²

A second program, YOLT-101, uses a similar adenine base-editing strategy with a different delivery system. In three participants with heterozygous FH given a single infusion at 0.6 mg per kilogram, circulating PCSK9 dropped by about 74% and LDL-C fell by roughly 52% at 24 weeks, with the effects remaining durable.³³ These are tiny trials, and long-term safety data are years away. But the idea of a one-and-done treatment for a condition that currently requires lifelong medication is genuinely revolutionary if it pans out. The key unknowns are off-target edits (unintended changes elsewhere in the genome) and whether the durability holds over five, ten, or twenty years.

How the Evidence for Cholesterol Lowering Was Built

The case that lowering cholesterol prevents heart disease did not arrive fully formed. It was assembled over decades from dietary trials, drug trials, and population studies, and the earlier experiments were not always clean. A 1990 review traced the arc: an early hospital-based diet trial in Los Angeles showed that replacing saturated fat with polyunsaturated fat reduced coronary events; the Oslo study paired a low-saturated-fat diet with smoking cessation and showed a significant drop in coronary disease alongside a 13% cholesterol reduction; a large World Health Organization trial of clofibrate cut heart attacks by 20% but puzzlingly saw a 37% rise in total mortality (a finding that haunted cholesterol skeptics for years, though no causal link to the drug was established). The Lipid Research Clinics trial, using the bile-acid sequestrant cholestyramine, finally showed that an 8% reduction in cholesterol led to a 19% reduction in coronary events.³⁴

By the late 1980s, a review synthesizing these trials and observational data concluded that the percent reduction in coronary risk was proportional to the degree of cholesterol lowering, and that the relationship was continuous from the highest to the lowest cholesterol levels studied.³⁵ The arrival of statins in the 1990s then provided a cleaner, more tolerable way to test the hypothesis at larger scale, and the results were consistent enough to make cholesterol lowering a central pillar of cardiovascular prevention. The messy early history matters because it explains why cholesterol skepticism persists in some corners: the pre-statin evidence really was ambiguous at times, and some of the early drugs really did cause harm.

ALDH2 Deficiency and Cholesterol

A genetic variant worth knowing about, particularly if you are of East Asian descent, involves the enzyme ALDH2. Best known for its role in breaking down acetaldehyde from alcohol (it is the variant responsible for the “Asian flush” reaction), ALDH2 also turns out to regulate cholesterol production. Research in mice has shown that when ALDH2 is absent or carries the common rs671 mutation, the cholesterol-production enzyme HMG-CoA reductase is stabilized rather than being tagged for destruction. The result is overproduction of cholesterol in both the liver and the blood.³⁶ The rs671 variant is carried by an estimated 540 million people, mostly of East Asian ancestry. If you flush after drinking, you may also have a genetic nudge toward higher cholesterol that has nothing to do with your diet, and the mouse data suggest statins can counteract it.